Respiratory symptoms that develop between the ages of 18 and 30 may hold prognostic value for later decline in lung function.
Regular use of aspirin may slow the progression of emphysema.
A recent study examined whether nebulized glycopyrrolate is safe to use in patients with severe COPD and comorbid cardiovascular risk factors.
The safety of concurrently administering nebulized glycopyrrolate with long-acting beta agonists was examined in 3 studies.
Forced expiratory volume in 1 second and length of hospital stay were assess to determine the benefit of endobronchial valve placement vs standard of care in emphysema.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
Higher doses were independently linked to slower change in emphysema, especially among former smokers
Treatment with full-dose angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was found to slow disease progression in patients with emphysema.
Sunovion announces Utibron Neohaler, an inhalation powder for the long term maintenance treatment of airflow obstruction in COPD patients.